Mifepristone inhibits extracellular matrix formation in uterine leiomyoma.

[1]  A. Armstrong,et al.  Clinical management of leiomyoma. , 2015, Obstetrics and gynecology clinics of North America.

[2]  S. Mesiano,et al.  Role of nuclear progesterone receptor isoforms in uterine pathophysiology. , 2015, Human reproduction update.

[3]  W. Catherino,et al.  Alternative therapies in management of leiomyomas. , 2014, Fertility and sterility.

[4]  J. Segars,et al.  Leiomyoma Cells in 3-Dimensional Cultures Demonstrate an Attenuated Response to Fasudil, a Rho-Kinase Inhibitor, When Compared to 2-Dimensional Cultures , 2014, Reproductive Sciences.

[5]  J. Castellot,et al.  Matrix production and remodeling as therapeutic targets for uterine leiomyoma , 2014, Journal of Cell Communication and Signaling.

[6]  J. Segars,et al.  Liarozole inhibits transforming growth factor-β3--mediated extracellular matrix formation in human three-dimensional leiomyoma cultures. , 2014, Fertility and sterility.

[7]  I. Osterloh,et al.  Long-term treatment of uterine fibroids with ulipristal acetate ☆. , 2014, Fertility and sterility.

[8]  A. Kakade,et al.  Mifepristone: current knowledge and emerging prospects. , 2014, Journal of the Indian Medical Association.

[9]  Xueqiong Zhu,et al.  Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. , 2013, Fertility and sterility.

[10]  L. Pawelczyk,et al.  [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology]. , 2013, Ginekologia polska.

[11]  A. Al-Hendy,et al.  Racial and Ethnic Differences in the Pathogenesis and Clinical Manifestations of Uterine Leiomyoma , 2013, Seminars in Reproductive Medicine.

[12]  F. Petraglia,et al.  Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. , 2013, Fertility and sterility.

[13]  C. Sánchez,et al.  Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial , 2013, International journal of women's health.

[14]  Md Soriful Islam,et al.  Uterine leiomyoma: available medical treatments and new possible therapeutic options. , 2013, The Journal of clinical endocrinology and metabolism.

[15]  S. Bulun,et al.  Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. , 2013, Endocrine reviews.

[16]  I. Manyonda,et al.  Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[17]  W. Catherino,et al.  Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production. , 2012, Fertility and sterility.

[18]  W. Catherino,et al.  Development and validation of a three-dimensional in vitro model for uterine leiomyoma and patient-matched myometrium. , 2012, Fertility and sterility.

[19]  A. Caplan,et al.  Proteoglycans of uterine fibroids and keloid scars: similarity in their proteoglycan composition. , 2012, The Biochemical journal.

[20]  L. Nieman,et al.  Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. , 2011, Fertility and sterility.

[21]  S. Bulun,et al.  Progesterone is essential for maintenance and growth of uterine leiomyoma. , 2010, Endocrinology.

[22]  K. Gemzell‐Danielsson,et al.  Mifepristone for Treatment of Uterine Leiomyoma: A Prospective Randomized Placebo Controlled Trial , 2010 .

[23]  J. Segars,et al.  Transforming Growth Factor β3 Regulates the Versican Variants in the Extracellular Matrix-Rich Uterine Leiomyomas , 2009, Reproductive Sciences.

[24]  A. Williams,et al.  Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. , 2009, Human reproduction.

[25]  Fiona Fennessy,et al.  Image-guided thermal therapy of uterine fibroids. , 2009, Seminars in ultrasound, CT, and MR.

[26]  K. Mishra,et al.  Low‐dose mifepristone in treatment of uterine leiomyoma: A randomised double‐blind placebo‐controlled clinical trial , 2009, The Australian & New Zealand journal of obstetrics & gynaecology.

[27]  N. Ohara.  A putative role of versican in uterine leiomyomas. , 2009, Clinical and experimental obstetrics & gynecology.

[28]  D. Baird,et al.  Growth of uterine leiomyomata among premenopausal black and white women , 2008, Proceedings of the National Academy of Sciences.

[29]  W. Catherino,et al.  Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells , 2008, Clinical endocrinology.

[30]  K. Fiscella,et al.  CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. , 2008, Obstetrics and gynecology.

[31]  K. Chwalisz,et al.  A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. , 2007, Fertility and sterility.

[32]  W. Catherino,et al.  Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays. , 2007, Fertility and sterility.

[33]  Y. Cheon,et al.  Spatio-temporal expression and regulation of dermatopontin in the early pregnant mouse uterus. , 2006, Molecules and cells.

[34]  M. Payson,et al.  Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids , 2004, Genes, chromosomes & cancer.

[35]  J. Steinauer,et al.  Systematic Review of Mifepristone for the Treatment of Uterine Leiomyomata , 2004, Obstetrics and gynecology.

[36]  H. Matsuo,et al.  Sex steroidal regulation of uterine leiomyoma growth and apoptosis. , 2004, Human reproduction update.

[37]  H. Matsuo,et al.  Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. , 2004, Human Reproduction.

[38]  L. Benet,et al.  Antiprogestin Pharmacodynamics, Pharmacokinetics, and Metabolism: Implications for Their Long-Term Use , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[39]  Hong Wang,et al.  Expression of progesterone receptors A and B and insulin-like growth factor-I in human myometrium and fibroids after treatment with a gonadotropin-releasing hormone analogue. , 2002, Fertility and sterility.

[40]  T. Wight,et al.  Versican: a versatile extracellular matrix proteoglycan in cell biology. , 2002, Current opinion in cell biology.

[41]  B. O’Malley,et al.  Reproductive functions of progesterone receptors. , 2002, Recent progress in hormone research.

[42]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[43]  G. Zhu,et al.  [Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata]. , 1998, Zhonghua fu chan ke za zhi.

[44]  S. Yen,et al.  Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. , 1995, Fertility and sterility.

[45]  S. Yen,et al.  Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. , 1994, Human reproduction.

[46]  P. Weatherall,et al.  An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. , 1993, The Journal of clinical endocrinology and metabolism.

[47]  A. Tiltman.  The effect of progestins on the mitotic activity of uterine fibromyomas. , 1985, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.